When Should You SELL Your Stocks (8 Reasons to Sell Your Stocks) Click to watch on Youtube.

GLOBAL BLOOD THERAPEUTICS Stock Forecast

NASDAQ:GBT BUY

$67.00 (-0.0597%)

Volume: 4.81M

Closed: Aug 16, 2022

Hollow Logo Score: 3.896

GLOBAL BLOOD THERAPEUTICS Stock Forecast

BUY NASDAQ:GBT
$67.00 (-0.0597%)

Volume: 4.81M

Closed: Aug 16, 2022

Score Hollow Logo 3.896

GBT Price Targets and Analyst Ratings NASDAQ:GBT

GBT Forecast. What You Should Know.

GBT Historical Ratings and Targets

FAQ

What are analyst ratings?
Analyst ratings are recommendations made by various stock analysts. Public companies are rated by analysts who monitor their industries. These stock ratings result from a thorough evaluation of a traded company using known metrics such as sales, earnings, and potential catalysts. Read More...

What to keep in mind using analyst ratings?
The best way to use analyst ratings is to supplement your investment research. Please do not rely on them blindly; instead, use them as one tool in your decision-making process. Also, be sure to pay attention to the date of the rating. Analyst ratings can change quickly, and a rating that was accurate six months ago might not be relevant today. Read More...

What is a price target in trading?
A price target is a stock market term used by investors and analysts to indicate the level at which they believe a stock will trade. The price target is based on several factors, including a company's earnings, revenue, and valuation. Determining a price target can be tricky, as it is an estimate and not always accurate. However, it can guide investors looking to buy or sell a stock. Read More...

Unlock All Premium Features! Go Premium! Only $19.90/Month

Unlock the Top 5 candidates in every list
Unlock full Ultimate List Builder
Golden Star lists & Auto Portfolios
Possible Runners & Moving Average lists
Ad-free browsing
Save data in PDF

About GLOBAL BLOOD THERAPEUTICS

GLOBAL BLOOD THERAPEUTICS Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, ... Read more

.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT